Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

CASSIS

Financiado

Cerrado

A single-cell atlas of human soft tissue sarcoma ecosystems with focus on mechan...

A single-cell atlas of human soft tissue sarcoma ecosystems with focus on mechanisms of immune evasion Soft tissue sarcomas (STS) are rare, aggressive cancers. About 50% of patients with high-risk STS die within 5 years after diagnosis, highlighting the need for novel treatment approaches. A major obstacle for novel treatment desig... ver más

31/01/2025

GERMAN CANCER RESE...

Presupuesto desconocido

Líder del proyecto

DEUTSCHES KREBSFORSCHUNGSZENTRUM HEIDELBERG No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2025-01-31

HORIZON-MSCA-2021-PF-01-01: MSCA Postdoctoral Fellowships 2021 ExpectedOutcome:

I+D

Cerrada hace 3 años

0% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

Participantes

GERMAN CANCER RESEARCH CENTE...

Lider

Proyectos interesantes

STIC-GBM

Medical Technol...

Data Science

174K€ Cerrado

OncoSeq

Medical Technol...

Data Science

150K€ Cerrado

IMMUcan

Medical Technol...

Data Science

36M€ Cerrado

EXPAND IT

Medical Technol...

Data Science

3M€ Cerrado

MelImmuneOrg

Medical Technol...

Data Science

185K€ Cerrado

SpatialTMEMetabolism

Medical Technol...

Data Science

1M€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 23 meses Fecha Inicio: 2023-02-01
Fecha Fin: 2025-01-31

Líder del proyecto

DEUTSCHES KREBSFORSCHUNGSZENTRUM HEIDELBERG No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Soft tissue sarcomas (STS) are rare, aggressive cancers. About 50% of patients with high-risk STS die within 5 years after diagnosis, highlighting the need for novel treatment approaches. A major obstacle for novel treatment design is our limited understanding of STS as ecosystems, shaped by diverse tumor cells and their interactions with cells of the microenvironment. Emerging strategies that target cellular relationships in STS are promising, such as immune checkpoint inhibition. First clinical trials assessing immune checkpoint inhibition were promising, but success varied greatly among different STS subtypes and a rational selection of patients was not available. A comprehensive description of the complex cellular diversity and interactions in STS tumor ecosystems and links to disease progression are currently missing. Here we will combine simultaneous detection of single-cell transcriptomes and cell surface proteins with 32-plex immunofluorescence imaging to characterize STS tumor and immune cell diversity with single-cell spatial resolution in seven STS subtypes. The STS subtypes include dedifferentiated liposarcoma, Ewing sarcoma, myxoid/round cell liposarcoma, clear cell sarcoma, desmoplastic small round cell tumor, fibromyxoid sarcoma, and solitary fibrous tumor, present with poor prognosis and are promising candidates for immunotherapies. Objectives are (1) to characterize the cellular diversity and tumor-immune interactions in STS ecosystems using simultaneous single-cell transcriptomics and cell surface proteomics, (2) to profile the STS immunoenvironment with single-cell spatial resolution in situ, and (3) to functionally assess candidate tumor-immune interactions in vitro. This project will provide the first single-cell atlas for seven STS subtypes and will enable a better understanding of STS tumor ecosystems, pave the way for novel precision oncology approaches, and facilitate the identification of candidates for immunotherapy clinical trials.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores